FDA approves 2-dose biologic Exdensur for severe eosinophilic asthma in patients 12 and older, reducing exacerbations and hospital visits.
Overcoming acquired treatment resistance is one of the major challenges in the fight against cancer. While combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback